Abnormalities in signaling pathways in diabetic nephropathy

References

• Pagtalunan ME, Miller PL, Jumping-Eagle S et al. Podocyte loss and progressive glomerular injury in Type II diabetes. J. Clin. Invest.99(2), 342–348 (1997).
   PubMed Web of Science ®Google Scholar
• Wharram BL, Goyal M, Wiggins JE et al. Podocyte depletion causes glomerulosclerosis: diphtheria toxin-induced podocyte depletion in rats expressing human diphtheria toxin receptor transgene. J. Am. Soc. Nephrol.16(10), 2941–2952 (2005).
   PubMed Web of Science ®Google Scholar
• Meyer TW, Bennett PH, Nelson RG. Podocyte number predicts long-term urinary albumin excretion in Pima Indians with Type II diabetes and microalbuminuria. Diabetologia42(11), 1341–1344 (1999).
   PubMed Web of Science ®Google Scholar
• Morcos M, Borcea V, Isermann B et al. Effect of α-lipoic acid on the progression of endothelial cell damage and albuminuria in patients with diabetes mellitus: an exploratory study. Diabetes Res. Clin. Pract.52(3), 175–183 (2001).
   PubMed Web of Science ®Google Scholar
• Isermann B, Vinnikov IA, Madhusudhan T et al. Activated protein C protects against diabetic nephropathy by inhibiting endothelial and podocyte apoptosis. Nat. Med.13(11), 1349–1358 (2007).
   PubMed Web of Science ®Google Scholar
• Zhao HJ, Wang S, Cheng H et al. Endothelial nitric oxide synthase deficiency produces accelerated nephropathy in diabetic mice. J. Am. Soc. Nephrol.17(10), 2664–2669 (2006).
   PubMed Web of Science ®Google Scholar
• Nakagawa T, Sato W, Glushakova O et al. Diabetic endothelial nitric oxide synthase knockout mice develop advanced diabetic nephropathy. J. Am. Soc. Nephrol.18(2), 539–550 (2007).
   PubMed Web of Science ®Google Scholar
• Toyoda M, Najafian B, Kim Y, Caramori ML, Mauer M. Podocyte detachment and reduced glomerular capillary endothelial fenestration in human Type 1 diabetic nephropathy. Diabetes56(8), 2155–2160 (2007).
   PubMed Web of Science ®Google Scholar
• Oldfield MD, Bach LA, Forbes JM et al. Advanced glycation end products cause epithelial-myofibroblast transdifferentiation via the receptor for advanced glycation end products (RAGE). J. Clin. Invest.108(12), 1853–1863 (2001).
   PubMed Web of Science ®Google Scholar
• Heilig CW, Liu Y, England RL et al. D-glucose stimulates mesangial cell GLUT1 expression and basal and IGF-I-sensitive glucose uptake in rat mesangial cells: implications for diabetic nephropathy. Diabetes46(6), 1030–1039 (1997).
   PubMed Web of Science ®Google Scholar
• D’Agord Schaan B, Lacchini S, Bertoluci MC, Irigoyen MC, Machado UF, Schmid H. Increased renal GLUT1 abundance and urinary TGF-β 1 in streptozotocin-induced diabetic rats: implications for the development of nephropathy complicating diabetes. Horm. Metab. Res.33(11), 664–669 (2001).
   PubMed Web of Science ®Google Scholar
• Horie K, Miyata T, Maeda K et al. Immunohistochemical colocalization of glycoxidation products and lipid peroxidation products in diabetic renal glomerular lesions. Implication for glycoxidative stress in the pathogenesis of diabetic nephropathy. J. Clin. Invest.100(12), 2995–3004 (1997).
   PubMed Web of Science ®Google Scholar
• Skolnik EY, Yang Z, Makita Z, Radoff S, Kirstein M, Vlassara H. Human and rat mesangial cell receptors for glucose-modified proteins: potential role in kidney tissue remodelling and diabetic nephropathy. J. Exp. Med.174(4), 931–939 (1991).
   PubMed Web of Science ®Google Scholar
• Makita Z, Radoff S, Rayfield EJ et al. Advanced glycosylation end products in patients with diabetic nephropathy. N. Engl. J. Med.325(12), 836–842 (1991).
   PubMed Web of Science ®Google Scholar
• Derubertis FR, Craven PA. Activation of protein kinase C in glomerular cells in diabetes. Mechanisms and potential links to the pathogenesis of diabetic glomerulopathy. Diabetes43(1), 1–8 (1994).
   PubMed Web of Science ®Google Scholar
• Babazono T, Kapor-Drezgic J, Dlugosz JA, Whiteside C. Altered expression and subcellular localization of diacylglycerol-sensitive protein kinase C isoforms in diabetic rat glomerular cells. Diabetes47(4), 668–676 (1998).
   PubMedGoogle Scholar
• Yamamoto T, Nakamura T, Noble NA, Ruoslahti E, Border WA. Expression of transforming growth factor β is elevated in human and experimental diabetic nephropathy. Proc. Natl Acad. Sci. USA90(5), 1814–1818 (1993).
   PubMed Web of Science ®Google Scholar
• Ziyadeh FN, Sharma K, Ericksen M, Wolf G. Stimulation of collagen gene expression and protein synthesis in murine mesangial cells by high glucose is mediated by autocrine activation of transforming growth factor-β. J. Clin. Invest.93(2), 536–542 (1994).
   PubMed Web of Science ®Google Scholar
• Marre M, Bernadet P, Gallois Y et al. Relationships between angiotensin I converting enzyme gene polymorphism, plasma levels, and diabetic retinal and renal complications. Diabetes43(3), 384–388 (1994).
   PubMed Web of Science ®Google Scholar
• Doria A, Warram JH, Krolewski AS. Genetic predisposition to diabetic nephropathy. Evidence for a role of the angiotensin I-converting enzyme gene. Diabetes43(5), 690–695 (1994).
   PubMed Web of Science ®Google Scholar
• Huang W, Gallois Y, Bouby N et al. Genetically increased angiotensin I-converting enzyme level and renal complications in the diabetic mouse. Proc. Natl Acad. Sci. USA98(23), 13330–13334 (2001).
   PubMed Web of Science ®Google Scholar
• Takahashi N, Hagaman JR, Kim HS, Smithies O. Minireview: computer simulations of blood pressure regulation by the renin–angiotensin system. Endocrinology144(6), 2184–2190 (2003).
   PubMedGoogle Scholar
• Kakoki M, Takahashi N, Jennette JC, Smithies O. Diabetic nephropathy is markedly enhanced in mice lacking the bradykinin B2 receptor. Proc. Natl Acad. Sci. USA101(36), 13302–13305 (2004).
   PubMed Web of Science ®Google Scholar
• Kakoki M, Kizer CM, Yi X et al. Senescence-associated phenotypes in Akita diabetic mice are enhanced by absence of bradykinin B2 receptors. J. Clin. Invest.116(5), 1302–1309 (2006).
   PubMed Web of Science ®Google Scholar
• Allard J, Buleon M, Cellier E et al. ACE inhibitor reduces growth factor receptor expression and signaling but also albuminuria through B2-kinin glomerular receptor activation in diabetic rats. Am. J. Physiol.293(4), F1083–1092 (2007).
   PubMed Web of Science ®Google Scholar
• Alric C, Pecher C, Cellier E et al. Inhibition of IGF-I-induced Erk 1 and 2 activation and mitogenesis in mesangial cells by bradykinin. Kidney Int.62(2), 412–421 (2002).
   PubMedGoogle Scholar
• Prabhakar SS. Role of nitric oxide in diabetic nephropathy. Semin. Nephrol.24(4), 333–344 (2004).
   PubMed Web of Science ®Google Scholar
• Mohan S, Reddick RL, Musi N et al. Diabetic eNOS knockout mice develop distinct macro- and microvascular complications. Lab. Invest.88(5), 515–528 (2008).
   PubMedGoogle Scholar
• Kanetsuna Y, Takahashi K, Nagata M et al. Deficiency of endothelial nitric-oxide synthase confers susceptibility to diabetic nephropathy in nephropathy-resistant inbred mice. Am. J. Pathol.170(5), 1473–1484 (2007).
   PubMed Web of Science ®Google Scholar
• Forbes MS, Thornhill BA, Park MH, Chevalier RL. Lack of endothelial nitric-oxide synthase leads to progressive focal renal injury. Am. J. Pathol.170(1), 87–99 (2007).
   PubMedGoogle Scholar
• Dreieicher E, Beck KF, Lazaroski S et al. Nitric oxide inhibits glomerular TGF-β signaling via SMOC-1. J. Am. Soc. Nephrol. (2009).
   PubMedGoogle Scholar
• Amiri F, Shaw S, Wang X et al. Angiotensin II activation of the JAK/STAT pathway in mesangial cells is altered by high glucose. Kidney Int.61(5), 1605–1616 (2002).
   PubMedGoogle Scholar
• Banes AK, Shaw S, Jenkins J et al. Angiotensin II blockade prevents hyperglycemia-induced activation of JAK and STAT proteins in diabetic rat kidney glomeruli. Am. J. Physiol.286(4), F653–659 (2004).
   PubMed Web of Science ®Google Scholar
• Wang X, Shaw S, Amiri F, Eaton DC, Marrero MB. Inhibition of the Jak/STAT signaling pathway prevents the high glucose-induced increase in TGF-β and fibronectin synthesis in mesangial cells. Diabetes51(12), 3505–3509 (2002).
   PubMed Web of Science ®Google Scholar
• Banes-Berceli AK, Shaw S, Ma G et al. Effect of simvastatin on high glucose- and angiotensin II-induced activation of the JAK/STAT pathway in mesangial cells. Am. J. Physiol.291(1), F116–F121 (2006).
   PubMed Web of Science ®Google Scholar
• Marrero MB, Banes-Berceli AK, Stern DM, Eaton DC. Role of the JAK/STAT signaling pathway in diabetic nephropathy. Am. J. Physiol.290(4), F762–768 (2006).
   PubMed Web of Science ®Google Scholar
• Berthier CC, Zhang H, Schin M et al. Enhanced expression of Janus kinase-signal transducer and activator of transcription pathway members in human diabetic nephropathy. Diabetes58(2), 469–477 (2009).
   PubMed Web of Science ®Google Scholar
• Logar CM, Brinkkoetter PT, Krofft RD, Pippin JW, Shankland SJ. Darbepoetin alfa protects podocytes from apoptosis in vitro and in vivo. Kidney Int.72(4), 489–498 (2007).
   PubMed Web of Science ®Google Scholar
• Mori H, Inoki K, Masutani K et al. The mTOR pathway is highly activated in diabetic nephropathy and rapamycin has a strong therapeutic potential. Biochem. Biophys. Res. Comm.384(4), 471–475 (2009).
   PubMed Web of Science ®Google Scholar
• Inoki K. Role of TSC-mTOR pathway in diabetic nephropathy. Diabetes Res. Clin. Pract.82(Suppl. 1), S59–S62 (2008).
   Google Scholar
• Lee MJ, Feliers D, Mariappan MM et al. A role for AMP-activated protein kinase in diabetes-induced renal hypertrophy. Am. J. Physiol.292(2), F617–F627 (2007).
   PubMed Web of Science ®Google Scholar
• Lee MN, Ha SH, Kim J et al. Glycolytic flux signals to mTOR through glyceraldehyde-3-phosphate dehydrogenase-mediated regulation of Rheb. Mol. Cell. Biol.29(14), 3991–4001 (2009).
   PubMed Web of Science ®Google Scholar
• Choo AY, Blenis J. Not all substrates are treated equally: implications for mTOR, rapamycin-resistance and cancer therapy. Cell Cycle8(4), 567–572 (2009).
   PubMed Web of Science ®Google Scholar
• Lloberas N, Cruzado JM, Franquesa M et al. Mammalian target of rapamycin pathway blockade slows progression of diabetic kidney disease in rats. J. Am. Soc. Nephrol.17(5), 1395–1404 (2006).
   PubMed Web of Science ®Google Scholar
• Hirano T, Kashiwazaki K, Moritomo Y, Nagano S, Adachi M. Albuminuria is directly associated with increased plasma PAI-1 and factor VII levels in NIDDM patients. Diabetes Res. Clin. Pract.36(1), 11–18 (1997).
   PubMedGoogle Scholar
• Eddy AA, Giachelli CM. Renal expression of genes that promote interstitial inflammation and fibrosis in rats with protein-overload proteinuria. Kidney Int.47(6), 1546–1557 (1995).
   PubMed Web of Science ®Google Scholar
• Fisher EJ, McLennan SV, Yue DK, Turtle JR. High glucose reduces generation of plasmin activity by mesangial cells. Microvasc. Res.53(2), 173–178 (1997).
   PubMedGoogle Scholar
• McLennan SV, Fisher E, Martell SY et al. Effects of glucose on matrix metalloproteinase and plasmin activities in mesangial cells: possible role in diabetic nephropathy. Kidney Int.77(Suppl.), S81–S87 (2000).
   Google Scholar
• Lee EA, Seo JY, Jiang Z et al. Reactive oxygen species mediate high glucose-induced plasminogen activator inhibitor-1 up-regulation in mesangial cells and in diabetic kidney. Kidney Int.67(5), 1762–1771 (2005).
   PubMed Web of Science ®Google Scholar
• Sassen S, Miska EA, Caldas C. MicroRNA-implications for cancer. Virchows Arch.452(1), 1–10 (2007).
   PubMedGoogle Scholar
• Kato M, Zhang J, Wang M et al. MicroRNA-192 in diabetic kidney glomeruli and its function in TGF-β-induced collagen expression via inhibition of E-box repressors. Proc. Natl Acad. Sci. USA104(9), 3432–3437 (2007).
   PubMed Web of Science ®Google Scholar
• Ina K, Kitamura H, Tatsukawa S, Takayama T, Fujikura Y. Glomerular podocyte endocytosis of the diabetic rat. J. Electron Microsc. (Tokyo)51(4), 275–279 (2002).
   PubMedGoogle Scholar
• Akilesh S, Huber TB, Wu H et al. Podocytes use FcRn to clear IgG from the glomerular basement membrane. Proc. Natl Acad. Sci. USA105(3), 967–972 (2008).
   PubMed Web of Science ®Google Scholar
• Kriz W, Hackenthal E, Nobiling R, Sakai T, Elger M, Hahnel B. A role for podocytes to counteract capillary wall distension. Kidney Int.45(2), 369–376 (1994).
   PubMedGoogle Scholar
• Durvasula RV, Petermann AT, Hiromura K et al. Activation of a local tissue angiotensin system in podocytes by mechanical strain. Kidney Int.65(1), 30–39 (2004).
   PubMed Web of Science ®Google Scholar
• Iglesias-de la Cruz MC, Ziyadeh FN, Isono M et al. Effects of high glucose and TGF-β1 on the expression of collagen IV and vascular endothelial growth factor in mouse podocytes. Kidney Int.62(3), 901–913 (2002).
   PubMed Web of Science ®Google Scholar
• Kitsiou PV, Tzinia AK, Stetler-Stevenson WG et al. Glucose-induced changes in integrins and matrix-related functions in cultured human glomerular epithelial cells. Am. J. Physiol. Renal Physiol.284(4), 671–679 (2003).
   PubMed Web of Science ®Google Scholar
• Chen HC, Chen CA, Guh JY, Chang JM, Shin SJ, Lai YH. Altering expression of α3β1 integrin on podocytes of human and rats with diabetes. Life Sci.67(19), 2345–2353 (2000).
   PubMed Web of Science ®Google Scholar
• Regoli M, Bendayan M. Alterations in the expression of the α3 β1 integrin in certain membrane domains of the glomerular epithelial cells (podocytes) in diabetes mellitus. Diabetologia40(1), 15–22 (1997).
   PubMedGoogle Scholar
• Jin DK, Fish AJ, Wayner EA et al. Distribution of integrin subunits in human diabetic kidneys. J. Am. Soc. Nephrol.7(12), 2636–2645 (1996).
   PubMed Web of Science ®Google Scholar
• Yoon S, Gingras D, Bendayan M. Alterations of vitronectin and its receptor α(v) integrin in the rat renal glomerular wall during diabetes. Am. J. Kidney Dis.38(6), 1298–1306 (2001).
   PubMed Web of Science ®Google Scholar
• Wei C, Moller CC, Altintas MM et al. Modification of kidney barrier function by the urokinase receptor. Nat. Med.14(1), 55–63 (2008).
   PubMed Web of Science ®Google Scholar
• Munger JS, Huang X, Kawakatsu H et al. The integrin α v β 6 binds and activates latent TGF β 1: a mechanism for regulating pulmonary inflammation and fibrosis. Cell96(3), 319–328 (1999).
   PubMed Web of Science ®Google Scholar
• Dessapt C, Baradez MO, Hayward A et al. Mechanical forces and TGFβ1 reduce podocyte adhesion through α3β1 integrin downregulation. Nephrol. Dial. Transplant.124(9), 2645–2655 (2009).
   Google Scholar
• Wu DT, Bitzer M, Ju W, Mundel P, Bottinger EP. TGF-β Concentration specifies differential signaling profiles of growth arrest/differentiation and apoptosis in podocytes. J. Am. Soc. Nephrol.16(11), 3211–3221 (2005).
   PubMed Web of Science ®Google Scholar
• Lee EY, Chung CH, Khoury CC et al. Monocyte chemoattractant protein-1/CCR2 loop, inducible by TGF-β, increases podocyte motility and albumin permeability. Am. J. Physiol. Renal Physiol.297(1), F85–F94 (2009).
   PubMed Web of Science ®Google Scholar
• Schiffer M, Bitzer M, Roberts IS et al. Apoptosis in podocytes induced by TGF-β and Smad7. J. Clin. Invest.108(6), 807–816 (2001).
   PubMed Web of Science ®Google Scholar
• Jung KY, Chen K, Kretzler M, Wu C. TGF-β1 regulates the PINCH-1-integrin-linked kinase-α-parvin complex in glomerular cells. J. Am. Soc. Nephrol.18(1), 66–73 (2007).
   PubMedGoogle Scholar
• Niranjan T, Murea M, Susztak K. The pathogenic role of notch activation in podocytes. Nephron Exp. Nephrol.111(4), e73–e79 (2009).
   PubMedGoogle Scholar
• Niranjan T, Bielesz B, Gruenwald A et al. The Notch pathway in podocytes plays a role in the development of glomerular disease. Nat. Med.14(3), 290–298 (2008).
   PubMed Web of Science ®Google Scholar
• Wada T, Pippin JW, Terada Y, Shankland SJ. The cyclin-dependent kinase inhibitor p21 is required for TGF-β1-induced podocyte apoptosis. Kidney Int.68(4), 1618–1629 (2005).
   PubMedGoogle Scholar
• Chow FY, Nikolic-Paterson DJ, Atkins RC, Tesch GH. Macrophages in streptozotocin-induced diabetic nephropathy: potential role in renal fibrosis. Nephrol. Dial. Transplant.19(12), 2987–2996 (2004).
   PubMed Web of Science ®Google Scholar
• Chow FY, Nikolic-Paterson DJ, Ozols E, Atkins RC, Rollin BJ, Tesch GH. Monocyte chemoattractant protein-1 promotes the development of diabetic renal injury in streptozotocin-treated mice. Kidney Int.69(1), 73–80 (2006).
   PubMed Web of Science ®Google Scholar
• Amann B, Tinzmann R, Angelkort B. ACE inhibitors improve diabetic nephropathy through suppression of renal MCP-1. Diabetes Care26(8), 2421–2425 (2003).
   PubMed Web of Science ®Google Scholar
• Chow F, Ozols E, Nikolic-Paterson DJ, Atkins RC, Tesch GH. Macrophages in mouse Type 2 diabetic nephropathy: correlation with diabetic state and progressive renal injury. Kidney Int.65(1), 116–128 (2004).
   PubMed Web of Science ®Google Scholar
• Gu L, Hagiwara S, Fan Q et al. Role of receptor for advanced glycation end-products and signalling events in advanced glycation end-product-induced monocyte chemoattractant protein-1 expression in differentiated mouse podocytes. Nephrol. Dial. Transplant.21(2), 299–313 (2006).
   PubMed Web of Science ®Google Scholar
• Burt D, Salvidio G, Tarabra E et al. The monocyte chemoattractant protein-1/cognate CC chemokine receptor 2 system affects cell motility in cultured human podocytes. Am. J. Pathol.171(6), 1789–1799 (2007).
   PubMedGoogle Scholar
• Tarabra E, Giunti S, Barutta F et al. Effect of the Mcp-1/Ccr2 system on nephrin expression in streptozotocin-treated mice and human cultured podocytes. Diabetes58(9), 2109–2118 (2009).
   PubMed Web of Science ®Google Scholar
• Dai C, Stolz DB, Kiss LP, Monga SP, Holzman LB, Liu Y. Wnt/β-catenin signaling promotes podocyte dysfunction and albuminuria. J. Am. Soc. Nephrol.20(9), 1997–2008 (2009).
   PubMed Web of Science ®Google Scholar
• Heikkila E, Ristola M, Endlich K et al. Densin and β-catenin form a complex and co-localize in cultured podocyte cell junctions. Mol. Cell. Biochem.305(1–2), 9–18 (2007).
   PubMedGoogle Scholar
• Teixeira Vde P, Blattner SM, Li M et al. Functional consequences of integrin-linked kinase activation in podocyte damage. Kidney Int.67(2), 514–523 (2005).
   PubMedGoogle Scholar
• Guo L, Sanders PW, Woods A, Wu C. The distribution and regulation of integrin-linked kinase in normal and diabetic kidneys. Am. J. Pathol.159(5), 1735–1742 (2001).
   PubMed Web of Science ®Google Scholar
• Han SY, Kang YS, Jee YH et al. High glucose and angiotensin II increase b1 integrin and integrin-linked kinase synthesis in cultured mouse podocytes. Cell Tissue Res.323(2), 321–332 (2006).
   PubMedGoogle Scholar
• Cooper ME, Vranes D, Youssef S et al. Increased renal expression of vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in experimental diabetes. Diabetes48(11), 2229–2239 (1999).
   PubMed Web of Science ®Google Scholar
• Baelde HJ, Eikmans M, Lappin DW et al. Reduction of VEGF-A and CTGF expression in diabetic nephropathy is associated with podocyte loss. Kidney Int.71(7), 637–645 (2007).
   PubMed Web of Science ®Google Scholar
• Hohenstein B, Hausknecht B, Boehmer K, Riess R, Brekken RA, Hugo CP. Local VEGF activity but not VEGF expression is tightly regulated during diabetic nephropathy in man. Kidney Int.69(9), 1654–1661 (2006).
   PubMed Web of Science ®Google Scholar
• Han SH, Yang S, Jung DS et al. Gene expression patterns in glucose-stimulated podocytes. Biochem. Biophys. Res. Commun.370(3), 514–518 (2008).
   PubMedGoogle Scholar
• Hoshi S, Nomoto K, Kuromitsu J, Tomari S, Nagata M. High glucose induced VEGF expression via PKC and ERK in glomerular podocytes. Biochem. Biophys. Res. Commun.290(1), 177–184 (2002).
   PubMed Web of Science ®Google Scholar
• Lee E-Y, Shim MS, Kim MJ, Hong SY, Shin YG, Chung CH. Angiotensin II receptor blocker attenuates overexpression of vascular endothelial growth factor in diabetic podocytes. Exp. Mol. Med.36(1), 65–70 (2004).
   PubMedGoogle Scholar
• Chen S, Lee JS, Iglesias-de la Cruz MC et al. Angiotensin II stimulates {alpha}3(IV) collagen production in mouse podocytes via TGF-β and VEGF signalling: implications for diabetic glomerulopathy. Nephrol. Dial. Transplant.20(7), 1320–1328 (2005).
   PubMedGoogle Scholar
• Chuang PY, He JC. Signaling in regulation of podocyte phenotypes. Nephron Physiol.111(2), p9–p15 (2009).
   PubMedGoogle Scholar
• Chen S, Kasama Y, Lee JS, Jim B, Marin M, Ziyadeh FN. Podocyte-derived vascular endothelial growth factor mediates the stimulation of alpha3(IV) collagen production by transforming growth factor-β1 in mouse podocytes. Diabetes53(11), 2939–2949 (2004).
   PubMed Web of Science ®Google Scholar
• Ichinose K, Maeshima Y, Yamamoto Y et al. 2-(8-hydroxy-6-methoxy-1-oxo-1h-2-benzopyran-3-yl) propionic acid, an inhibitor of angiogenesis, ameliorates renal alterations in obese Type 2 diabetic mice. Diabetes55(5), 1232–1242 (2006).
   PubMed Web of Science ®Google Scholar
• Yamamoto Y, Maeshima Y, Kitayama H et al. Tumstatin peptide, an inhibitor of angiogenesis, prevents glomerular hypertrophy in the early stage of diabetic nephropathy. Diabetes53(7), 1831–1840 (2004).
   PubMedGoogle Scholar
• Ichinose K, Maeshima Y, Yamamoto Y et al. Antiangiogenic endostatin peptide ameliorates renal alterations in the early stage of a Type 1 diabetic nephropathy model. Diabetes54(10), 2891–2903 (2005).
   PubMed Web of Science ®Google Scholar
• Sung SH, Ziyadeh FN, Wang A, Pyagay PE, Kanwar YS, Chen S. Blockade of vascular endothelial growth factor signaling ameliorates diabetic albuminuria in mice. J. Am. Soc. Nephrol.17(11), 3093–3104 (2006).
   PubMed Web of Science ®Google Scholar
• Foster RR, Saleem MA, Mathieson PW, Bates DO, Harper SJ. Vascular endothelial growth factor and nephrin interact and reduce apoptosis in human podocytes. Am. J. Physiol. Renal Physiol.288(1), F48–F57 (2005).
   PubMed Web of Science ®Google Scholar
• Guan F, Villegas G, Teichman J, Mundel P, Tufro A. Autocrine VEGF-A system in podocytes regulates podocin and its interaction with CD2AP. Am. J. Physiol. Renal Physiol.291(2), F422–F428 (2006).
   Web of Science ®Google Scholar
• Futrakul N, Butthep P, Vongthavarawat V et al. Early detection of endothelial injury and dysfunction in conjunction with correction of hemodynamic maladjustment can effectively restore renal function in Type 2 diabetic nephropathy. Clin. Hemorheol. Microcirc.34(3), 373–381 (2006).
   PubMed Web of Science ®Google Scholar
• Nakagawa T, Kosugi T, Haneda M, Rivard CJ, Long DA. Abnormal angiogenesis in diabetic nephropathy. Diabetes58(7), 1471–1478 (2009).
   PubMed Web of Science ®Google Scholar
• Thomas S, Vanuystel J, Gruden G et al. Vascular endothelial growth factor receptors in human mesangium in vitro and in glomerular disease. J. Am. Soc. Nephrol.11(7), 1236–1243 (2000).
   PubMed Web of Science ®Google Scholar
• Nakagawa T. Uncoupling of the VEGF-endothelial nitric oxide axis in diabetic nephropathy: an explanation for the paradoxical effects of VEGF in renal disease. Am. J. Physiol.292(6), F1665–F1672 (2007).
   PubMed Web of Science ®Google Scholar
• Chen S, Ziyadeh FN. Vascular endothelial growth factor and diabetic nephropathy. Curr. Diab. Rep.8(6), 470–476 (2008).
   PubMedGoogle Scholar
• Shibuya M, Claesson-Welsh L. Signal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesis. Exp. Cell Res.312(5), 549–560 (2006).
   PubMed Web of Science ®Google Scholar
• Rizkalla B, Forbes JM, Cao Z, Boner G, Cooper ME. Temporal renal expression of angiogenic growth factors and their receptors in experimental diabetes: role of the renin–angiotensin system. J. Hypertens.23(1), 153–164 (2005).
   PubMed Web of Science ®Google Scholar
• Lim HS, Lip GY, Blann AD. Angiopoietin-1 and angiopoietin-2 in diabetes mellitus: relationship to VEGF, glycaemic control, endothelial damage/dysfunction and atherosclerosis. Atherosclerosis180(1), 113–118 (2005).
   PubMed Web of Science ®Google Scholar
• Davis B, Dei Cas A, Long DA et al. Podocyte-specific expression of angiopoietin-2 causes proteinuria and apoptosis of glomerular endothelia. J. Am. Soc. Nephrol.18(8), 2320–2329 (2007).
   PubMed Web of Science ®Google Scholar
• Satchell SC, Anderson KL, Mathieson PW. Angiopoietin 1 and vascular endothelial growth factor modulate human glomerular endothelial cell barrier properties. J. Am. Soc. Nephrol.15(3), 566–574 (2004).
   PubMedGoogle Scholar
• Tsukada T, Yokoyama K, Arai T et al. Evidence of association of the ecNOS gene polymorphism with plasma NO metabolite levels in humans. Biochem. Biophys. Res. Comm.245(1), 190–193 (1998).
   PubMed Web of Science ®Google Scholar
• Veldman BA, Spiering W, Doevendans PA et al. The Glu298Asp polymorphism of the NOS 3 gene as a determinant of the baseline production of nitric oxide. J. Hypertens.20(10), 2023–2027 (2002).
   PubMed Web of Science ®Google Scholar
• Nakayama M, Yasue H, Yoshimura M et al. T-786–>C mutation in the 5´-flanking region of the endothelial nitric oxide synthase gene is associated with coronary spasm. Circulation99(22), 2864–2870 (1999).
   PubMed Web of Science ®Google Scholar
• Ksiazek P, Wojewoda P, Muc K, Buraczynska M. Endothelial nitric oxide synthase gene intron 4 polymorphism in Type 2 diabetes mellitus. Mol. Diagn.7(2), 119–123 (2003).
   PubMedGoogle Scholar
• Ezzidi I, Mtiraoui N, Mohamed MB, Mahjoub T, Kacem M, Almawi WY. Association of endothelial nitric oxide synthase Glu298Asp, 4b/a, and -786T>C gene variants with diabetic nephropathy. J. Diabetes Complications22(5), 331–338 (2008).
   PubMed Web of Science ®Google Scholar
• Zanchi A, Moczulski DK, Hanna LS, Wantman M, Warram JH, Krolewski AS. Risk of advanced diabetic nephropathy in Type 1 diabetes is associated with endothelial nitric oxide synthase gene polymorphism. Kidney Int.57(2), 405–413 (2000).
   PubMed Web of Science ®Google Scholar
• Hohenstein B, Hugo CP, Hausknecht B, Boehmer KP, Riess RH, Schmieder RE. Analysis of NO-synthase expression and clinical risk factors in human diabetic nephropathy. Nephrol. Dial. Transplant.23(4), 1346–1354 (2007).
   PubMedGoogle Scholar
• Quaggin SE, Coffman TM. Toward a mouse model of diabetic nephropathy: is endothelial nitric oxide synthase the missing link? J. Am. Soc. Nephrol.18(2), 364–366 (2007).
   PubMedGoogle Scholar
• Najafian B, Kim Y, Crosson JT, Mauer M. Atubular glomeruli and glomerulotubular junction abnormalities in diabetic nephropathy. J. Am. Soc. Nephrol.14(4), 908–917 (2003).
   PubMed Web of Science ®Google Scholar
• Du XL, Edelstein D, Rossetti L et al. Hyperglycemi-induced mitochondrial superoxide overproduction activates hexosamine pathway and induces plasminogen-activator inhibitor-1 expression by increasing Sp-1 glycosylation. Proc. Natl Acad. Sci. USA97, 12222–12226 (2000).
   PubMed Web of Science ®Google Scholar
• Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature414(6865), 813–820 (2001).
   PubMed Web of Science ®Google Scholar
• Gilbert RE, Marsden PA. Activated protein C and diabetic nephropathy. N. Engl. J. Med.358(15), 1628–1630 (2008).
   PubMedGoogle Scholar
• Fujiwara Y, Tagami S, Kawakami Y. Circulating thrombomodulin and hematological alterations in Type 2 diabetic patients with retinopathy. J. Atheroscler.Thromb.5(1), 21–28 (1998).
   PubMedGoogle Scholar
• Bader R, Bader H, Grund KE, Mackensen-Haen S, Christ H, Bohle A. Structure and function of the kidney in diabetic glomerulosclerosis. Correlations between morphological and functional parameters. Pathol. Res. Pract.167(2–4), 204–216 (1980).
   PubMed Web of Science ®Google Scholar
• Mauer SM, Steffes MW, Ellis EN, Sutherland DE, Brown DM, Goetz FC. Structural–functional relationships in diabetic nephropathy. J. Clin. Invest.74(4), 1143–1155 (1984).
   PubMed Web of Science ®Google Scholar
• Fioretto P, Mauer M. Histopathology of diabetic nephropathy. Semin. Nephrol.27(2), 195–207 (2007).
   PubMed Web of Science ®Google Scholar
• Zoja C, Donadelli R, Colleoni S et al. Protein overload stimulates RANTES production by proximal tubular cells depending on NF-κB activation. Kidney Int.53(6), 1608–1615 (1998).
   PubMed Web of Science ®Google Scholar
• Tang S, Leung JC, Abe K et al. Albumin stimulates interleukin-8 expression in proximal tubular epithelial cells in vitro and in vivo. J. Clin. Invest.111(4), 515–527 (2003).
   PubMed Web of Science ®Google Scholar
• Eddy AA, Kim H, Lopez-Guisa J, Oda T, Soloway PD. Interstitial fibrosis in mice with overload proteinuria: deficiency of TIMP-1 is not protective. Kidney Int.58(2), 618–628 (2000).
   PubMed Web of Science ®Google Scholar
• Wang Y, Chen J, Chen L, Tay YC, Rangan GK, Harris DC. Induction of monocyte chemoattractant protein-1 in proximal tubule cells by urinary protein. J. Am. Soc. Nephrol.8(10), 1537–1545 (1997).
   PubMed Web of Science ®Google Scholar
• Schmid H, Boucherot A, Yasuda Y et al. Modular activation of nuclear factor-κB transcriptional programs in human diabetic nephropathy. Diabetes55(11), 2993–3003 (2006).
   PubMed Web of Science ®Google Scholar
• Navarro JF, Milena FJ, Mora C, Leon C, Garcia J. Renal pro-inflammatory cytokine gene expression in diabetic nephropathy: effect of angiotensin-converting enzyme inhibition and pentoxifylline administration. Am. J. Nephrol.26(6), 562–570 (2006).
   PubMed Web of Science ®Google Scholar
• Tesch GH. Role of macrophages in complications of Type 2 diabetes. Clin. Exp. Pharmacol. Physiol.34(10), 1016–1019 (2007).
   PubMedGoogle Scholar
• Morcos M, Sayed AA, Bierhaus A et al. Activation of tubular epithelial cells in diabetic nephropathy. Diabetes51(12), 3532–3544 (2002).
   PubMed Web of Science ®Google Scholar
• Mizuno M, Sada T, Kato M, Fukushima Y, Terashima H, Koike H. The effect of angiotensin II receptor blockade on an end-stage renal failure model of Type 2 diabetes. J. Cardiovasc. Pharmacol.48(4), 135–142 (2006).
   PubMedGoogle Scholar
• Agarwal R. Anti-inflammatory effects of short-term pioglitazone therapy in men with advanced diabetic nephropathy. Am. J. Physiol. Renal Physiol.290(3), F600–F605 (2006).
   PubMed Web of Science ®Google Scholar
• Yozai K, Shikata K, Sasaki M et al. Methotrexate prevents renal injury in experimental diabetic rats via anti-inflammatory actions. J. Am. Soc. Nephrol.16(11), 3326–3338 (2005).
   PubMed Web of Science ®Google Scholar
• Usui HK, Shikata K, Sasaki M et al. Macrophage scavenger receptor-a-deficient mice are resistant against diabetic nephropathy through amelioration of microinflammation. Diabetes56(2), 363–372 (2007).
   PubMedGoogle Scholar
• Chander PN, Gealekman O, Brodsky SV et al. Nephropathy in Zucker diabetic fat rat is associated with oxidative and nitrosative stress: prevention by chronic therapy with a peroxynitrite scavenger ebselen. J. Am. Soc. Nephrol.15(9), 2391–2403 (2004).
   PubMed Web of Science ®Google Scholar